NCT06773403View on ClinicalTrials.gov

Upadacitinib for Prurigo Nodularis

PHASE4RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions
Prurigo Nodularis
Interventions
DRUG

Upadacitinib

All subject start on 15mg. At week 8 subjects may increase to 30mg if the investigators deems it necessary.

Trial Locations (1)

08520

RECRUITING

Eczema Treatment Center of New Jersey, East Windsor

Sponsors

Collaborators (1)

AbbVie
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Psoriasis Treatment Center of Central New Jersey

OTHER